Impact of Maternal Eating Disorders on Pediatric Respiratory Health in Europe
December 10, 2025
Brand Name :
Bromfed-DM
Synonyms :
brompheniramine/pseudoephedrine/dextromethorphan
Class :
Non-narcotic Combos; Antitussive/Antihistamine/Decongestant Combos
Dosage Forms & Strengths
brompheniramine/pseudoephedrine/dextromethorphan
Oral syrup
(2mg/30mg/10mg)/5mL
(3mg/50mg /30mg)/5mL
Oral elixir
(1mg/15mg /5mg)/5mL
Indicated for Nasal congestion and cough
Bromfed DM- 10 ml or 2 teaspoonfuls orally every 4 hours
Do not exceed more than 6 doses/day
Bromaline DM- 20 ml or 4 teaspoonfuls orally every 4-6 hours
Do not exceed more than 4 doses/day
Bromdex D- 5ml or 1 teaspoonful orally every 4 hours;
Do not exceed more than 4 doses/day
Dosage Forms & Strengths
Oral syrup
(2mg/30mg/10mg)/5mL
(3mg/50mg /30mg)/5mL
Oral elixir
(1mg/15mg /5mg)/5mL
Bromfed DM- 10 ml or 2 teaspoonfuls orally every 4 hours
Do not exceed more than 6 doses/day
Bromaline DM- 20 ml or 4 teaspoonfuls orally every 4-6 hours
Do not exceed more than 4 doses/day
Bromdex D- 5ml or 1 teaspoonful orally every 4 hours;
Do not exceed more than 4 doses/day
Bromaline DM For <6 years- As directed by the physician 6-12 years: 10 ml or 2 teaspoonfuls orally every 4 hours
Do not exceed more than 4 doses/day
For >12 years- 20 ml or 4 teaspoonfuls orally every 4-6 hours
Do not exceed more than 4 doses/day
For 6 months-2 years: As directed by the physician
For 2-6 years- 2.5 ml or half teaspoonful orally every 4 hours
Do not exceed more than 6 doses/day
For 6-12 years- 5 ml or 1 teaspoonful orally every 4 hours
Do not exceed more than 6 doses/day
For >12 years- 10 ml or 2 teaspoonfuls orally every 4 hours
Do not exceed more than 6 doses/day
Bromdex D For <6 years- As directed by the physician For 6-12 years- 2.5 mL orally every 6 hours as required Do not exceed more than 4 doses each day For >12 years- 5 mL orally every 6 hours as required; Do not exceed more than 4 doses each day
Refer to the adult dosing
Actions and Spectrum:
brompheniramine competitively blocks the histamines from linking to H1 receptors.
This causes an antimuscarinic activity that penetrates CNS, causing a pronounced potential to produce sedation.
pseudoephedrine stimulates alpha-adrenergic receptors that cause vasoconstriction and bronchodilation.
dextromethorphan suppresses cough and acts on the medullary cough center.
Frequency not defined
Drowsiness
Dizziness
Dry mouth, nose, or throat
Arrhythmia
Palpitations
Thickening of mucus
GI disturbances
Convulsion
Excitability
Weakness
Tremor
Black Box Warning:
None
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
Category C
Breastfeeding warnings:
The drug is contraindicated during lactation as it is excreted in the breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
brompheniramine is an antihistamine drug that blocks the effects of histamine, a chemical released during allergic reactions. It acts as a competitive antagonist at histamine H1 receptors, preventing histamine from binding to and activating these receptors.
pseudoephedrine stimulates the alpha-adrenergic receptors, which cause vasoconstriction and bronchodilation. dextromethorphan is a cough suppressant acting on the medullary cough center.
pseudoephedrine acts as a selective alpha-1 adrenergic receptor agonist. It stimulates the alpha-1 adrenergic receptors on the smooth muscle lining the walls of blood vessels in the nasal passages.
Pharmacodynamics:
Pharmacodynamics includes histamine H1 receptor antagonism, anticholinergic effects, and sedative effects.
Pharmacokinetics:
Absorption
The onset takes place in 15-30 min
The duration of action is achieved in 3-9 hours (brompheniramine) and 3-8 hours for pseudoephedrine
The peak plasma concentration is attained in 2-5 hr (brompheniramine)
Distribution
The volume of distribution is 11.7 L/kg for brompheniramine
Metabolism
MAO inhibitors metabolize brompheniramine in the liver and phenylephrine in the intestine. P450 metabolizes the drug and CYP2D6 hepatic enzymes
Elimination and Excretion
The half-life is 11.8-34.7 hours for brompheniramine and 2-4 hours in excreted in the urine
Administration:
brompheniramine/pseudoephedrine dextromethorphan is administered through the oral route. It is provided in oral solutions, elixirs, and suspension.
Patient information leaflet
Generic Name: brompheniramine/pseudoephedrine/dextromethorphan
Pronounced: brom-fen-EER-a-meen, soo-doe-e-FED-rin, dex-troe-me-THOR-fan
Why do we use brompheniramine/pseudoephedrine/dextromethorphan
This drug belongs to nasal decongestant used to relieve respiratory tract congestion, rhinitis, and allergic rhinitis.